Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Receivables (2019 - 2025)

Cresco Labs (CRLBF) has disclosed Receivables for 6 consecutive years, with $51.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables rose 0.97% year-over-year to $51.6 million, compared with a TTM value of $51.6 million through Dec 2024, up 0.97%, and an annual FY2024 reading of $51.6 million, up 0.97% over the prior year.
  • Receivables was $51.6 million for Q4 2024 at Cresco Labs, up from $51.1 million in the prior quarter.
  • Across five years, Receivables topped out at $56.5 million in Q4 2022 and bottomed at $30.1 million in Q4 2020.
  • Average Receivables over 5 years is $46.5 million, with a median of $51.1 million recorded in 2023.
  • The sharpest move saw Receivables surged 72.98% in 2020, then dropped 9.6% in 2023.
  • Year by year, Receivables stood at $30.1 million in 2020, then soared by 43.91% to $43.4 million in 2021, then soared by 30.23% to $56.5 million in 2022, then decreased by 9.6% to $51.1 million in 2023, then grew by 0.97% to $51.6 million in 2024.
  • Business Quant data shows Receivables for CRLBF at $51.6 million in Q4 2024, $51.1 million in Q4 2023, and $56.5 million in Q4 2022.